Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus capecitabine/cisplatin versus capecitabine/cisplatin in first-line advanced gastric or gastroesophageal junction adenocarcinoma
2007-004219-75Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck KGaA. Primary endpoint: progression-free survival. Started Jan 2008; status: terminated.
02
Drugs
cetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2007-004219-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004219-75.